NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC.

This is a study exploring cemiplimab, an immunotherapy medicine, before surgery for treating resectable lung cancer, liver cancer, and head and neck cancer in multiple groups.

an immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

resectable lung cancer: Some patients have a tumor that is “resectable,” which means that it is able to be removed with surgery.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03916627

Clinical Trial Site: Sinai

To see all available clinical trials click here.